National Unit for Full-Stage Development
of Immune Cell Gene Therapy (NDIT)

NDIT supports the full-stage development of immune cell gene therapies for solid tumors,
accelerating the path from research to early clinical application and expanding future treatment opportunities for patients.

OUR VISION

Improving Survival and Quality of Life for Patients with Solid Tumors

OUR GOAL

Advance Immune Cell Gene Therapies for Solid Tumors

• 
  Establishing
  Next-Generation Immune Cell Therapy Platforms for Solid Tumors
  Building core technology foundations for CAR-T, TCR-T, and TIL therapies.
• 
  Developing
  Precision-Targeting Technologies for Solid Tumors Based on Tumor-Specific and Neo-Antigens
  Establishing
  a foundation for personalized therapies to overcome tumor heterogeneity.
• 
  Establishing Clinically Applicable CMC/QC Systems
  Establishing manufacturing processes and quality control standards for clinical-grade cell and vector production.
• 
  Advancing Early Clinical Research
  Evaluating safety, pharmacokinetics, toxicology, and antitumor efficacy to generate clinical evidence.
• 
  Building an Advanced Regenerative Medicine Ecosystem for Solid Tumors
  Establishing a full-stage platform connecting basic research, preclinical development, manufacturing, and clinical application.